Randox Cerebral arrays are designed for the simultaneous measurement of analytes associated with nervous system dysfunctions such as cerebrovascular disease, Alzheimer’s disease and Multiple Sclerosis (MS). Neurological disorders can affect the central, somatic and autonomic nervous system. At the molecular level, many analytes have been found to be involved in the pathophysiology of this complex interacting system. Proteins such as neuron specific enolase (NSE) are considered to be neurochemical markers of brain damage due to stroke or head injury and also appear to have predictive value for outcome after acute stroke. BDNF and GFAP among others have also been linked to Alzheimer’s disease and MS. Inflammatory processes have increasingly been shown to be implicated in the pathogenesis of cerebrovascular disease, and CRP has been identified as a predictor of future stroke risk.
Cerebral Array I • Brain-Derived Neurotrophic Factor (BDNF) • Heart Type Fatty Acid Binding Protein (H-FABP) • Glial Fibrillary Acidic Protein (GFAP) • Interleukin-6 (IL-6)
Cerebral Array II • Neuron Specific Enolase (NSE) • Neutrophil Gelatinase-Associated Lipocalin (NGAL) • Soluble Tumour Necrosis Factor Receptor I (sTNFRI) • D-dimer • Thrombomodulin (TM) • C-reactive protein (CRP)
Key Benefits • Measures up to six biomarkers simultaneously • Human serum, plasma and cerebrospinal fluid (CSF) samples • Small sample volume, just 35 - 100μl • For use with fully and semi-automated Evidence analysers • Simple sample preparation • Wide measuring range • Excellent sensitivity, precision and recovery
Write a review
Sharing your experience will help scientists like you. Achieve Reviewer Status and Win an iPad 3 (All reviews published will be entered into the next drawing on January 30th 2014).